HC Wainwright restated their buy rating on shares of Liquidia (NASDAQ:LQDA - Free Report) in a report released on Thursday morning,Benzinga reports. HC Wainwright currently has a $29.00 price objective on the stock. HC Wainwright also issued estimates for Liquidia's Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.25) EPS and FY2029 earnings at $0.51 EPS.
Other research analysts have also issued reports about the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price objective on shares of Liquidia in a research note on Thursday, January 9th. Wells Fargo & Company began coverage on shares of Liquidia in a research note on Friday, December 20th. They set an "overweight" rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $26.63.
Get Our Latest Stock Report on Liquidia
Liquidia Trading Up 3.6 %
Shares of NASDAQ:LQDA traded up $0.54 during trading on Thursday, reaching $15.66. The company's stock had a trading volume of 794,613 shares, compared to its average volume of 933,982. The stock has a market capitalization of $1.34 billion, a PE ratio of -9.61 and a beta of 0.07. Liquidia has a 12 month low of $8.26 and a 12 month high of $16.92. The firm's 50 day simple moving average is $14.87 and its two-hundred day simple moving average is $12.27.
Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The company had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Research analysts anticipate that Liquidia will post -1.51 EPS for the current fiscal year.
Insider Activity at Liquidia
In other Liquidia news, insider Rajeev Saggar sold 2,445 shares of Liquidia stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the completion of the sale, the insider now directly owns 267,943 shares of the company's stock, valued at $3,483,259. The trade was a 0.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Russell Schundler sold 16,393 shares of the company's stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the sale, the general counsel now owns 573,478 shares of the company's stock, valued at $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,245 shares of company stock worth $843,326 in the last 90 days. 30.10% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Liquidia
Several hedge funds have recently modified their holdings of LQDA. BNP Paribas Financial Markets increased its holdings in Liquidia by 735.1% during the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock valued at $1,402,000 after buying an additional 123,402 shares during the period. Barclays PLC boosted its position in Liquidia by 265.0% during the 3rd quarter. Barclays PLC now owns 99,984 shares of the company's stock valued at $999,000 after acquiring an additional 72,591 shares in the last quarter. Whitefort Capital Management LP increased its holdings in shares of Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company's stock valued at $17,020,000 after acquiring an additional 927,546 shares during the period. JPMorgan Chase & Co. raised its position in shares of Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after acquiring an additional 210,753 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Liquidia by 144.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock worth $3,903,000 after purchasing an additional 230,820 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.
Liquidia Company Profile
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
See Also
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
